Immunotherapy of metastatic and autochthonous liver cancer with IL-15/IL-15Rα fusion protein

Liang Cheng; Xuexiang Du; Lishan Su; Shengdian Wang

doi:10.4161/21624011.2014.963409

Immunotherapy of metastatic and autochthonous liver cancer with IL-15/IL-15Rα fusion protein

Oncoimmunology. 2014 Dec 21;3(11):e963409. doi: 10.4161/21624011.2014.963409. eCollection 2014 Nov.

Authors

Liang Cheng¹, Xuexiang Du², Lishan Su¹, Shengdian Wang³

Affiliations

¹ Key Laboratory of Infection and Immunity; Institute of Biophysics; Chinese Academy of Sciences ; Beijing China ; Lineberger Comprehensive Cancer Center; School of Medicine; The University of North Carolina at Chapel Hill ; Chapel Hill, NC USA.
² Key Laboratory of Infection and Immunity; Institute of Biophysics; Chinese Academy of Sciences ; Beijing China ; University of Chinese Academy of Sciences ; Beijing China.
³ Key Laboratory of Infection and Immunity; Institute of Biophysics; Chinese Academy of Sciences ; Beijing China.

Abstract

Liver cancer has a poor prognosis. Our recent study demonstrates that hyper-IL-15, composed of IL-15 and the sushi domain of IL-15 receptor α chain, provides an effective therapy against well-established metastatic and autochthonous liver cancers in mouse models by triggering activation and expansion of hepatic CD8⁺ T cells.

Keywords: CD8+ T cell; IFNγ; hyper-IL-15; immunotherapy; liver cancer.

Abstract

Grants and funding